Treatment of Heparin-Induced Thrombocytopenia (HIT)
Immediately discontinue all heparin products and start a non-heparin anticoagulant at therapeutic doses—argatroban, bivalirudin, danaparoid, fondaparinux, or a direct oral anticoagulant (DOAC)—based on renal function and clinical context 1.
Immediate Management Steps
When HIT is suspected or confirmed, execute the following algorithm:
1. Stop All Heparin Exposure
- Discontinue unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) immediately
- Remove heparin flushes from IV lines
- Check all medications for heparin content (including heparin-coated catheters)
2. Initiate Non-Heparin Anticoagulation
The choice of agent depends primarily on renal function:
For patients with normal renal function:
- Argatroban, lepirudin, or danaparoid are preferred options 2
- Fondaparinux is an acceptable alternative 1
- Bivalirudin can be used, particularly in cardiac surgery settings 2
For patients with renal insufficiency:
- Argatroban is the preferred agent because it is hepatically metabolized 2
- Avoid lepirudin and danaparoid as they are renally cleared
Dosing principle: Use therapeutic doses, not prophylactic doses, even in isolated HIT without thrombosis 3. This is critical—approximately one-third to one-half of HIT cases develop thrombosis, and the prothrombotic state persists despite thrombocytopenia 1.
3. Avoid Vitamin K Antagonists (Warfarin) Initially
Do not start warfarin until:
- Platelet count recovers to >150 × 10⁹/L 4
- Patient has received therapeutic anticoagulation with a non-heparin agent for at least 5 days
- INR is therapeutic (>2.0) for at least 2 consecutive days while overlapping with the non-heparin anticoagulant 4
Rationale: Starting warfarin during acute HIT can cause venous limb gangrene due to initial protein C depletion, which worsens the prothrombotic state 4. If warfarin was already started, reverse it with vitamin K 4.
Duration of Anticoagulation
For isolated HIT (thrombocytopenia without thrombosis):
- Continue therapeutic anticoagulation for at least 4 weeks 4
For HIT with thrombosis (HITT):
- Continue therapeutic anticoagulation for at least 3-4 months 4
- May require longer duration depending on thrombosis location and reversibility of risk factors
Emerging Role of Direct Oral Anticoagulants (DOACs)
DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) are increasingly used off-label for acute HIT 5, 6. They offer significant practical advantages:
- Oral administration (no IV access needed)
- No monitoring required
- More cost-effective than parenteral agents
- No need for transition therapy
However, DOACs should only be used after initial stabilization with a parenteral agent if:
- Patient can take oral medications
- No significant bleeding risk
- Platelet count is recovering (some experts wait until >50 × 10⁹/L)
The 2018 ASH guidelines conditionally recommend DOACs as an option but note limited evidence at that time 1. More recent data from 2024 support their use in appropriate cases 5.
Special Situations
Cardiac Surgery with Acute HIT
Bivalirudin is the preferred anticoagulant for cardiopulmonary bypass in patients requiring urgent cardiac surgery 2, 1.
Hemodialysis
- Argatroban or danaparoid can be used for anticoagulation during dialysis
- Fondaparinux is another option
Critical Pitfalls to Avoid
Do NOT use prophylactic doses of anticoagulation—always use therapeutic doses even without documented thrombosis 3
Do NOT start warfarin early—this can cause catastrophic limb gangrene 4
Do NOT give platelet transfusions unless life-threatening bleeding occurs, as this can worsen thrombosis
Do NOT wait for laboratory confirmation to stop heparin and start alternative anticoagulation if clinical suspicion is moderate-to-high (4Ts score ≥4) 1
Do NOT use LMWH as an alternative—it cross-reacts with HIT antibodies in 80-90% of cases
Monitoring Treatment
- Monitor platelet counts daily until recovery and stabilization
- For argatroban: monitor aPTT (target 1.5-3× baseline)
- For fondaparinux: no routine monitoring needed
- For DOACs: no routine monitoring needed
The key to successful HIT management is rapid recognition, immediate heparin cessation, and prompt initiation of therapeutic-dose non-heparin anticoagulation tailored to renal function and clinical context.